Review on defensive roles of thymoquinone nanobiosensoring prospective in opposition to cancer.

A Mohamed Sikkander*

Department of Chemistry, Velammal Engineering College, Chennai, India

Abstract

Thymoquinone (TQ), the most important bioactive constituent of Nigella sativa, has been originating to exhibit anticancer effects in plentiful preclinical studies. Due to its multi targeting character, TQ interferes in an extensive assortment of tumorigenic processes and counteracts carcinogenesis, malicious growth, incursion, exodus, and angiogenesis. Moreover, TQ can exclusively sensitize tumor cells on the way to predictable cancer treatments (e.g., chemotherapy, immunotherapy, and radiotherapy) and at the same time lessen psychoanalysis connected lethal effects in regular cells. In this review, we summarized the adjuvant prospective of TQ as observed in an assortment of in vitro and in vivo animal models and discussed the pharmacological properties of TQ to diminish its additional role in potentiating the usefulness of usual remedial modalities specifically surgery, radiotherapy, chemotherapy, and immunotherapy. On the whole we suggest supplementary ample evaluation of TQ in preclinical and clinical levels to demarcate its obscure usefulness as a novel corresponding adjuvant remedy for cancer treatment.

The focal point on nanotechnology for enhanced bioavailability and drug deliverance is of increasing significance for organizing different human diseases. Therefore, copious nanoformulations have been urbanized for the oral bioavailability of different drugs. This appraisal introduces applications of nanomedicine to improve the biological actions of thymoquinone (TQ) to be in charge of dissimilar diseases in more than a few in vivo studies as a beginning analysis for human disease healing with nano-TQ. Nano-TQ successfully augments the anticancer roles of doxorubicin by up principle of P53 and downward guideline of Bcl2 and potentiates paclitaxel's apoptosis in MCF-7 breast cancer cells. In addition nano-TQ protects in opposition to diabetes, inflammation, CNS, and hepatotoxicity, essentially by enhancement of organs' antioxidant condition. We sum up the pros and cons of several FDA approved nanoparticle-based therapeutics and talk about the roadblocks in clinical translation, along with probable nano-TQ strategies to conquer these roadblocks. From this assessment we can bring to a close that nano-TQ may be measured as a talented nutraceutical for human being healthiness.

Keywords: Nanonutraceuticals, thymoquinone, plasma proteins, bioavailability, anticarcinogenic

Accepted on 25 February, 2021

Introduction

Botanical and normal drugs have an extensive, recognized history in treating several diseases. Nigella sativa grows inside the Mediterranean and within Western Asian areas.

N. sativa is one of the majority well-known herbs used in Islamic long-established medication. The N. sativa seeds have a lot of pharmacological properties for instance antioxidant, anticarcinogenic, antihypertensive, and antidiabetic (Figure 1). Thymoquinone (TQ) is the major component of N. sativa and has influential anticancer, antioxidant, antimicrobial, antihistaminic, immunomodulatory, and anti-inflammatory natal properties. TQ has extensive nutraceutical potential that includes anticancer uses, anti-inflammatory, and antioxidant, but it's far above the ground insecurity , speedy abolition, and more than 99% necessary to plasma proteins restrictions the clinical result of TQ treatment . More than a few well-designed, comprehensive reviews casing on top of aspects have been presented.



Figure 1. *Biological activities of thymoquinone.*

Nanonutraceuticals have talented properties that help to conquer the boundaries of a medicinethat has a taperedtherapeutic window or small bioavailability. Nanonutraceuticals make available defense and diminish renal clearance for a long-drawn-out TQ pharmacological consequence. As an perfect nanonutraceutical, TQ would be delivered to the target tissue or organ, where gratis TQ could then reach a therapeutic attentiveness and be maintained for a required time. Nanomaterials can effortlessly

penetrate the biological membranes and make available sustained let loose of TQ to dissimilar body parts, and for that reason nanoformulated TQ would augment its bioavailability. Augmentation of drug and food constituents' deliverance and therapeutic special effects have been achieved by a wide hodgepodge of bottom-up encapsulation methods, such as on its own emulsions, dual emulsions, nanoprecipitation, or the ionic gelation technique, biopolymer side chains conjugations, and top-down methods such as the cold wet-milling method . In addition, nanoparticles (NPs) have been comprehensively used for drug deliverance augmentation such as carbon, ceramic, and chitosan NPs.

Glioblastoma multiforme (GBM)

Glioblastoma multiforme (GBM) is one of the the majority overwhelming brain tumors with norm continued existence of one year and presents only one of its kind challenges to therapy because of its violent behavior. Modern treatment approach involves surgery, radiotherapy, immunotherapy, and adjuvant chemotherapy even supposing most favorable management requires a multidisciplinary come up to and knowledge of probable complications from mutually the disease and its treatment. TQ interferes in a wide range of tumorigenic processes and frustrate carcinogenesis, malignant growth, incursion, exodus, and angiogenesis.

A most important neuroepithelial tumor of the brain, characterized by a belligerent clinical phenotype resultant from inter- and intrapatient genomic and histopathological assortment. In the latest reclassification of the World Health Organization (WHO), the GBMs are listed in the group of disseminate astrocytic and oligodendroglial tumors shimmering their exceedingly malignant activities It constitutes more than 40% of every one malignant brain tumors and in the order of 54.4% all malignant gliomas with mean age at diagnosis being 64 years and 1.5 times more ordinary in men than women.

In this assessment we summarized the probable role of TQ in dissimilar signaling pathway in GBM that have undergone cure with average therapeutic modalities or with TQ. Overall we suggest further all-inclusive evaluation of TQ in preclinical and clinical level to describe its oblique helpfulness as work of fiction therapeutics to struggle the challenges for the treatment of GBM.

GI Cancers: Colon Cancer

The curative probable of TQ in two dissimilar murine colon cancer models, viz.1, 2-dimethyl hydrazine (DMH), and xenografts representation. In the DMH representation TQ was injected intra peritoneal and the diversity, dimension, and allocation of aberrant crypt foci (ACF) and tumors were dogged at Weeks 10, 20, and 30. TQ appreciably condensed the numbers and sizes of ACF by 86%, and tumor large quantity at Week 20 was reduced from 17.8 in the DMH group to 4.2 in mice injected with TQ. This outcome persisted, and tumors did not regroup even when TQ injection was discontinued for 10 wk; and immunostaining for capsize 3 cleavages in relic tumors inveterate greater than before apoptosis in retort to TQ.

In the xenograft mock-up of HCT116 colon cancer cells, TQ appreciably ($P < 0.05$) belated the expansion of the tumors with greater than before facts of apoptosis deduced from TUNEL tint of xenografts tumors sustaining the probable use of TQ as a therapeutic agent in human colorectal cancer.

Fore stomach cancer

Defense to mice aligned with benzo(a)pyrene [B(a)P] induced fore stomach carcinogenesis and chromosomal aberrations (CAs) in bone marrow cells by TQ was reported by Badary. From their surveillance it was anecdotal that daily intake of the compound before, after, or during disclosure to B(a)P considerably reduced the frequencies of CAs and dented cells compared to the vastly clastogenic commotion of B(a)P alone. In toting up, tumor occurrence and diversity was seen subdued in as much as 70 and 67%, correspondingly.

Fibrosarcoma

The augmentation inhibitory and antitumor effects of TQ were more premeditated by Badary and Gamal El Din in fibrosarcoma induced by 20-methylcholanthrene (MC) in male Swiss albino mice. TQ was originate effectual not only in drastically inhibiting tumor frequency and tumor burden (34% compared to 100% in control tumor-bearing mice), but it also delayed the onset of MC-induced fibrosarcoma tumors—investigative of chemo preventive exploit against MC-induced fibrosarcomas.

Ehrlich Ascites Carcinoma (EAC)

Badary measured achievable augmentation of the antitumor activity of cisplatin by TQ in Ehrlich ascites carcinoma (EAC)-deportment mice and legitimate that TQ (50 mg/l in drinking water), when given 5 days before and 5 days after single injection of cisplatin, abrogated cisplatin nephrotoxicity and potentiated the antitumor action of cisplatin. One more study reported by Badary in mice deportment EAC xenograft, renowned that TQ (10 mg/kg/day) in drinking water considerably improved the antitumor effect of Ifosfamide. Mice treated with Ifosfamide in mishmash with TQ showed less body mass loss and mortality rate compared to Ifosfamide monotherapy. These explanations reveal that TQ may get better the therapeutic usefulness of Ifosfamide, cisplatin and in adding together, reverses Ifosfamide- and cisplatin-induced nephrotoxicity by preventing renal GST exhaustion and lipid peroxide production and improving their antitumor efficiency.

Prostate Cancer

Kaseb experiential in a xenograft prostate tumor model that TQ introverted growth of C4–2B plagiaristic tumors in nude mice. This was connected with a spectacular decrease in androgen receptor, transcript factor E2F-1, and cyclin A as resolute by Western blot analysis. Their conclusion clearly put forward that TQ may prove to be an effectual agent in treating hormone sensitive, as well as hormone intractable, prostate cancers with realistic degree of selectivity. TQ was also shown in an additional study of human being prostate cancer (PC3 cells) xenograft to restrain the tumor growth and block angiogenesis with just about no toxic side effects.

Conclusion

Based on the preceding explanation, the therapeutic probable of TQ should not be destabilized even though lack of any study accounting their bioavailability, which needs to be pursued. Once a accord on its bioavailability emerges, intended Phase I clinical trials to authenticate its convenience in chemosensitization

and position as chemopreventive agent must be prioritized for dissimilar site-specific cancers. In the intervening time, efforts should keep on focusing on laboratory research to gain further in-depth considerate on its molecular method of accomplishment as well as to devise strategy to invent potent analogs with smallest amount to little side effects, with the decisive goal of translating the profit of this environment endowed compound for therapeutic uses for diseases afflict humans.

References

1. El-Far A, Kamal E, Moharam MS. Antioxidant and antinematodal effects of Nigella sativa and Zingiber officinale supplementations in ewes. Int J Pharm. Sci Rev Res. 2014;26:222–227.
2. El-Far, AH. Thymoquinone anticancer discovery: Possible mechanisms. Curr. Drug Discov Technol. 2015;12:80–89.
3. El-Far AH, Korshom MA, Mandour AA,et al. Hepatoprotective efficacy of Nigella sativa seeds dietary supplementation against lead acetate-induced oxidative damage in rabbit–purification and characterization of glutathione peroxidase. Biomed. Pharmacother. 2017;89:711–718.
4. Banerjee S, Padhye S, Azmi A, et al. Review on molecular and therapeutic potential of thymoquinone in cancer. Nutr. Cancer. 2010;62:938–946.
5. Darakhshan S, Pour AB, Colagar AH, et al, Thymoquinone and its therapeutic potentials. Pharmacol Res. 2015;95–96:138–158.
6. Salmani JM, Asghar S, Lv HX, et al. Aqueous solubility and degradation kinetics of the phytochemical anticancer thymoquinone; probing the effects of solvents, pH and light. Molecules 2014;19:5925–5939.
7. Alkharfy KM, Ahmad A, Khan RM, et al. Pharmacokinetic plasma behaviors of intravenous and oral bioavailability of thymoquinone in a rabbit model. Eur J Drug Metab Pharmacokinet. 2015;40:319–323.
8. Schneider-Stock R, Fakhoury IH, Zaki AM, et al. Thymoquinone: Fifty years of success in the battle against cancer models. Drug Discov Today. 2014;19:18–30.
9. Ballout F, Habli Z, Rahal ON, et al. Thymoquinone-based nanotechnology for cancer therapy: Promises and challenges. Drug Discov Today. 2018;23:1089–1098.
10. Gupta B, Ghosh KK. Thymoquinone In Nutraceuticals: Efficacy Safety and Toxicity. 2016;541–550.
11. Imran M, Rauf A, Khan IA, et al. Thymoquinone: A novel strategy to combat cancer: A review. Biomed Pharmacother. 2018;106:390–402.

***Correspondence to:**

A Mohamed Sikkander

Department of Chemistry,

Velammal Engineering College,

Chennai-INDIA.

E-mail: ams240868@gmail.com